J. Becker
University of Tübingen
6 Papers
67 Citations
J. Becker is an academic researcher from University of Tübingen. The author has contributed to research in topics: Prostatectomy & Prostate cancer. The author has an hindex of 5, co-authored 6 publications.
Chat about Author
Papers
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation.
Stephanie G. C. Kroeze,Christoph Henkenberens,Nina Sophie Schmidt-Hegemann,Marco M. E. Vogel,Simon Kirste,J. Becker,Irene A. Burger,Thorsten Derlin,Peter Bartenstein,Matthias Eiber,Michael Mix,Christian la Fougère,Hans Christiansen,Claus Belka,Stephanie E. Combs,Anca L. Grosu,A. Müller,Matthias Guckenberger +17 more
TL;DR: In this cohort of patients with oligorecurrent PCa, concurrent ADT with MDT improved bRFS significantly, but a large number of patients treated withMDT were spared from ADT for 2yr, although a greater need for other salvage therapies was observed.
40
Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy
Ann-Kathrin Oehus,Stephanie G. C. Kroeze,Nina-Sophie Schmidt-Hegemann,Marco M. E. Vogel,Simon Kirste,Simon Kirste,J. Becker,Irene A. Burger,Thorsten Derlin,Peter Bartenstein,Matthias Eiber,Michael Mix,Christian la Fougère,Claus Belka,Claus Belka,Stephanie E. Combs,Anca-Ligia Grosu,Anca-Ligia Grosu,Arndt-Christian Müller,Matthias Guckenberger,Hans Christiansen,Christoph Henkenberens +21 more
TL;DR: RT as MDT based on PSMA - PET of all metastases of recurrent prostate cancer after RP and sRT represents a viable treatment option for well-informed and well-selected patients.
Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy—a multicenter retrospective study
N-S Schmidt-Hegemann,Stephanie G. C. Kroeze,Christoph Henkenberens,Marco M. E. Vogel,Simon Kirste,J. Becker,Irene A. Burger,Thorsten Derlin,Peter Bartenstein,Matthias Eiber,Michael Mix,Christian la Fougère,Arndt-Christian Müller,Anca-L. Grosu,Stephanie E. Combs,Stephanie E. Combs,Hans Christiansen,Matthias Guckenberger,Claus Belka +18 more
TL;DR: Overall, BRFS was dependent on patterns of metastatic disease, and MDR of PSMA PET-positive oligo-metastases can be offered considering that about one-third of the patients progressed within a median follow-up of 16 months.
19
Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy.
Marco M. E. Vogel,Stephanie G. C. Kroeze,Christoph Henkenberens,Nina-Sophie Schmidt-Hegemann,Simon Kirste,J. Becker,Irene A. Burger,Thorsten Derlin,Peter Bartenstein,Michael Mix,Christian la Fougère,Matthias Eiber,Hans Christiansen,Claus Belka,Anca L. Grosu,Arndt-Christian Müller,Matthias Guckenberger,Stephanie E. Combs,Stephanie E. Combs +18 more
TL;DR: A prognostic risk classification for biochemical relapse-free survival (bRFS) for patients after PSMA-PET-guided MDT after radical prostatectomy was developed and internally validated.
Combining 68Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study.
Simon Kirste,Stephanie G. C. Kroeze,Christoph Henkenberens,Nina-Sophie Schmidt-Hegemann,Marco M. E. Vogel,J. Becker,Constantinos Zamboglou,Irene A. Burger,Thorsten Derlin,Peter Bartenstein,Juri Ruf,Christian la Fougère,Matthias Eiber,Hans Christiansen,Stephanie E. Combs,Arndt-Christian Müller,Claus Belka,Matthias Guckenberger,Anca-Ligia Grosu +18 more
TL;DR: In this article, the authors compared oncological outcomes and toxicity between PET/CT-directed RT and PDRT plus elective RT (eRT; i.e., prostate bed, pelvic or paraaortal nodes) in a large retrospective multicenter study.